

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated November 29, 2022 (the “**Prospectus**”) of 3D Medicines Inc. (the “**Company**”).

This announcement is for information purpose only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus carefully for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933 as amended (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except that Offer Shares may be offered, sold or delivered (a) in the United States solely to qualified institutional buyers in reliance on Rule 144A or another exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act or (b) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

In connection with the Global Offering, China Securities (International) Corporate Finance Company Limited as stabilizing manager (the “**Stabilizing Manager**”) (or its affiliates or any person acting for it), on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action, which, if taken, will be done at the sole and absolute discretion of the Stabilizing Manager (or its affiliates or any person acting for it) and in what the Stabilizing Manager reasonably regards as the best interest of the Company and may be discontinued at any time. Any such stabilizing action is required to be brought to an end on the 30th day after the last day for lodging applications under the Hong Kong Public Offering being Friday, January 6, 2023. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that no stabilizing action can be taken on the Stock Exchange to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Friday, January 6, 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.



3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares in the Global Offering	: 16,350,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 1,635,000 Shares (subject to reallocation)
Number of International Offer Shares	: 14,715,000 Shares (subject to reallocation and the Over-allotment Option)
Maximum Offer Price	: HK\$26.24 per Offer Share, plus brokerage of 1%, AFRC transaction levy of 0.00015%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	: HK\$0.001 per Share
Stock code	: 1244


Joint Sponsors



Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers



Joint Bookrunners and Joint Lead Managers



Joint Lead Managers



**IMPORTANT NOTICE TO INVESTORS:
FULLY ELECTRONIC APPLICATION PROCESS**

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the Prospectus or printed copies of any application forms to the public in relation to the Hong Kong Public Offering.

The Prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under the “HKEXnews > New Listings > New Listing Information” section, and our website at www.3d-medicines.com. If you require a printed copy of the Prospectus, you may download and print from the website addresses above.

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online via the **HK eIPO White Form** service in the **IPO App** (which can be downloaded by searching “**IPO App**” in App Store or Google Play or downloaded at www.hkeipo.hk/IPOApp or www.tricorglobal.com/IPOApp) or at www.hkeipo.hk; or
- (2) apply through the **CCASS EIPO** service to electronically cause HKSCC Nominees to apply on your behalf, including by:
 - (i) instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf; or
 - (ii) (if you are an existing **CCASS Investor Participant**) giving **electronic application instructions** through the CCASS Internet System (<https://ip.ccass.com>) or through the CCASS Phone System (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input **electronic application instructions** for CCASS Investor Participants through HKSCC’s Customer Service Centre by completing an input request.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed Prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

If you are an intermediary, broker or agent, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses above.

Please refer to “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details on the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **HK eIPO White Form** service or the **CCASS EIPO** service must be for a minimum of 500 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.

3D Medicines Inc. (Maximum Offer Price of HK\$26.24 per Hong Kong Offer Share)
NUMBER OF HONG KONG OFFER SHARES THAT MAY BE APPLIED FOR AND PAYMENTS

<u>No. of Hong Kong Offer Shares applied for</u>	<u>Amount payable on application</u>	<u>No. of Hong Kong Offer Shares applied for</u>	<u>Amount payable on application</u>	<u>No. of Hong Kong Offer Shares applied for</u>	<u>Amount payable on application</u>	<u>No. of Hong Kong Offer Shares applied for</u>	<u>Amount payable on application</u>
	<i>HK\$</i>		<i>HK\$</i>		<i>HK\$</i>		<i>HK\$</i>
500	13,252.23	5,000	132,522.30	30,000	795,133.79	100,000	2,650,445.99
1,000	26,504.46	6,000	159,026.76	35,000	927,656.10	200,000	5,300,891.97
1,500	39,756.69	7,000	185,531.22	40,000	1,060,178.39	300,000	7,951,337.95
2,000	53,008.92	8,000	212,035.68	45,000	1,192,700.69	400,000	10,601,783.93
2,500	66,261.15	9,000	238,540.14	50,000	1,325,222.99	500,000	13,252,229.92
3,000	79,513.39	10,000	265,044.59	60,000	1,590,267.59	600,000	15,902,675.91
3,500	92,765.61	15,000	397,566.90	70,000	1,855,312.19	700,000	18,553,121.89
4,000	106,017.84	20,000	530,089.20	80,000	2,120,356.79	800,000	21,203,567.87
4,500	119,270.07	25,000	662,611.49	90,000	2,385,401.38	817,500*	21,667,395.92

* Maximum number of Hong Kong Offer Shares you may apply for.

No application for any other number of Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

THE LISTING APPLICATION

We have applied to the Listing Committee for the listing of, and permission to deal in (i) the Shares in issue (including the Shares to be converted from the Preferred Shares); and (ii) the Shares to be issued pursuant to the Capitalization Issue and the Global Offering (including the additional Shares which may be issued pursuant to the exercise of the Over-allotment Option). Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. (Hong Kong time) on Thursday, December 15, 2022, it is expected that dealings in the Shares on the Main Board of the Stock Exchange will commence at 9:00 a.m. (Hong Kong time) on Thursday, December 15, 2022.

STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises (i) the Hong Kong Public Offering of initially 1,635,000 Hong Kong Offer Shares (subject to reallocation) and (ii) the International Offering of initially 14,715,000 International Offer Shares (subject to reallocation and the Over-allotment Option).

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering is subject to reallocation as detailed in the section headed “*Structure of the Global Offering – The Hong Kong Public Offering – Reallocation*” in the Prospectus. In particular, subject to the requirements under Practice Note 18 of the Listing Rules and Guidance Letter HKEX-GL91-18, the Joint Representatives may, at their sole and absolute discretion, reallocate Offer Shares of the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to clawback mechanism as described in the section headed “*Structure of the Global Offering – The Hong Kong Public Offering – Reallocation*” in the Prospectus, then the maximum number of the Offer Shares available under the Hong Kong Public Offering after any such reallocation shall not exceed 3,270,000 Offer Shares, representing 20% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), and the final Offer Price shall be fixed at HK\$22.96 per Offer Share (being the low-end of the Offer Price range stated in the Prospectus). Further details on the circumstances under which the above guidance letter would apply are set out in the section titled “*Structure of the Global Offering*” in the Prospectus.

Under the International Underwriting Agreement, we expect to grant the Over-allotment Option to the International Underwriters, exercisable by the Joint Representatives (on behalf of the International Underwriters) in whole or in part at their sole and absolute discretion at any time from the date of the International Underwriting Agreement until 30 days after the last day for the lodging of applications under the Hong Kong Public Offering, to require our Company to issue and allot up to 2,452,500 additional Offer Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering, to cover over-allocations in the International Offering, if any.

If the Over-allotment Option is exercised in full, the additional International Offer Shares to be issued pursuant thereto will represent approximately 0.95% of the total issued share capital of our Company immediately after the completion of the Global Offering and the exercise of the Over-allotment Option. In the event that the Over-allotment Option is exercised, we will make an announcement which will be posted on our website at www.3d-medicines.com and the website of the Stock Exchange at www.hkexnews.hk, respectively.

PRICING

The Offer Price will not be more than HK\$26.24 per Offer Share and is expected to be not less than HK\$22.96 per Offer Share unless otherwise announced by our Company no later than the morning of the last day for lodging applications under the Hong Kong Public Offering.

Applicants under the Hong Kong Public Offering are required to pay, on application, the maximum Offer Price of HK\$26.24 per Offer Share plus the brokerage fee of 1.0%, AFRC transaction levy of 0.00015%, SFC transaction levy of 0.0027%, and the Stock Exchange trading fee of 0.005% payable on each Offer Share, subject to refund if the Offer Price as finally determined is less than HK\$26.24 per Offer Share.

EXPECTED TIMETABLE

Hong Kong Public Offering commences 9:00 a.m. on Tuesday, November 29, 2022

Latest time for completing electronic applications under
the **HK eIPO White Form** service through
one of the ways below: 11:30 a.m. on
Wednesday, December 7, 2022

- the **IPO App**, which can be downloaded by
searching “**IPO App**” in App Store or
Google Play or downloaded at
www.hkeipo.hk/IPOApp or **www.tricorglobal.com/IPOApp**
- the designated website **www.hkeipo.hk**

Application lists for the Hong Kong Public Offering open 11:45 a.m. on
Wednesday, December 7, 2022

Latest time for (a) completing payment for the **HK eIPO White Form**
applications by effecting internet banking transfer(s) or PPS payment
transfer(s) and (b) giving **electronic application instructions** to
HKSCC 12:00 noon on
Wednesday, December 7, 2022

If you are instructing your **broker** or **custodian** who is a CCASS Clearing
Participant or a CCASS Custodian Participant to give **electronic**
application instructions via CCASS terminals to apply for the Hong Kong
Offer Shares on your behalf, you are advised to contact your
broker or **custodian** for the latest time for giving such instructions
which may be different from the latest time as stated above.

Application lists close 12:00 noon on
Wednesday, December 7, 2022

Expected Price Determination Date Wednesday, December 7, 2022

Announcement of:

- the Offer Price;
- indications of the level of interest in the International
Offering and the level of applications in the
Hong Kong Public Offering; and
- the basis of allocations of the Hong Kong Offer Shares
to be published on our website at **www.3d-medicines.com**
and the website of the Hong Kong Stock Exchange
at **www.hkexnews.hk** on or before Wednesday, December 14, 2022

Results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be available through a variety of channels, including

- in the announcement to be posted on our website at www.3d-medicines.com and the website of the Hong Kong Stock Exchange at www.hkexnews.hk by no later than 9:00 a.m. on Wednesday, December 14, 2022
- from the "IPO Results" function in the **IPO App** or the designated results of allocations website at www.hkeipo.hk/IPOResult (or www.tricor.com.hk/ipo/result) with a "search by ID" function from 8:00 a.m. on Wednesday, December 14, 2022 to 12:00 midnight on Tuesday, December 20, 2022
- from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Wednesday, December 14, 2022 to Monday, December 19, 2022 (exclude Saturday, Sunday and public holiday in Hong Kong)

Dispatch/Collection of Share certificates or deposit of Share certificates into CCASS in respect of wholly or partially successful applications under the Hong Kong Public Offering on or before. Wednesday, December 14, 2022

Dispatch/Collection of **HK eIPO White Form** e-Auto Refund payment instructions/refund cheques on or before. Wednesday, December 14, 2022

Dealings in the Shares on the Hong Kong Stock Exchange expected to commence at. 9:00 a.m. on Thursday, December 15, 2022

Note: All dates and times refer to Hong Kong local dates and times.

The application for the Hong Kong Offer Shares will commence on Tuesday, November 29, 2022 through to Wednesday, December 7, 2022. Such time period is longer than the normal market practice of three and a half (3.5) days. The application monies (including brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee) will be held by the receiving bank on behalf of our Company and the refund monies, if any, will be returned to the applicants without interest on or before Wednesday, December 14, 2022. Investors should be aware that the dealings in the Shares on the Stock Exchange are expected to commence on Thursday, December 15, 2022.

SETTLEMENT

Subject to the granting of, the listing of, and permission to deal in, the Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the Listing Date or on any other date as determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS. Investors should seek the advice of their stockbrokers or other professional advisers for details of those settlement arrangements and how such arrangements will affect their rights and interests.

ELECTRONIC APPLICATION CHANNELS

HK eIPO White Form service

You may submit your application through the **HK eIPO White Form** service in the **IPO App** or at **www.hkeipo.hk** (24 hours daily, except on the last application day) from 9:00 a.m. on Tuesday, November 29, 2022 until 11:30 a.m. on Wednesday, December 7, 2022 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Wednesday, December 7, 2022 or such later time as described under the section headed “*How to Apply for Hong Kong Offer Shares – C. Effect of Bad Weather and/or Extreme Conditions on the Opening and Closing of the Application Lists*” in the Prospectus.

CCASS EIPO service

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:

Tuesday, November 29, 2022	– 9:00 a.m. to 8:30 p.m.
Wednesday, November 30, 2022	– 8:00 a.m. to 8:30 p.m.
Thursday, December 1, 2022	– 8:00 a.m. to 8:30 p.m.
Friday, December 2, 2022	– 8:00 a.m. to 8:30 p.m.
Monday, December 5, 2022	– 8:00 a.m. to 8:30 p.m.
Tuesday, December 6, 2022	– 8:00 a.m. to 8:30 p.m.
Wednesday, December 7, 2022	– 8:00 a.m. to 12:00 noon

CCASS Investor Participants can input **electronic application instructions** 9:00 a.m. on Tuesday, November 29, 2022 until 12:00 noon on Wednesday, December 7, 2022 (24 hours daily, except on Wednesday, December 7, 2022, the last day for applications).

The latest time for inputting such **electronic application instructions** will be 12:00 noon on Wednesday, December 7, 2022, the last application day or such later time as described in the section headed “*How to Apply for Hong Kong Offer Shares – C. Effect of Bad Weather and/or Extreme Conditions on the Opening and Closing of the Application Lists*” in the Prospectus.

The times in this sub-section are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants and/or CCASS Investor Participants.

If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

The application monies (including the brokerage, SFC transaction levy, AFRC transaction levy, and the Stock Exchange trading fee) will be held by the receiving bank and on behalf of our Company after the closing of the application lists and the refund monies, if any, will be returned to the applicants without any interest on or before Wednesday, December 14, 2022.

Please refer to the sections “*Structure of the Global Offering*” and “*How to Apply for Hong Kong Offer Shares*” in the Prospectus for details of the conditions and procedures for applications for Hong Kong Offer Shares.

Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, in the IPO App and on the designated website (www.hkeipo.hk) for the HK eIPO White Form service.

PUBLICATION OF RESULTS

We expect to announce the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocations of the Hong Kong Offer Shares on Wednesday, December 14, 2022 on our website at www.3d-medicines.com and the website of the Stock Exchange at www.hkexnews.hk.

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration/certificate of incorporation numbers of successful applicants under the Hong Kong Public Offering will be available through a variety of channels at the times and dates and in the manner specified in the section “*How to Apply for Hong Kong Offer Shares – D. Publication of Results*” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the Offer Price as finally determined is less than the maximum Offer Price of HK\$26.24 per Offer Share (excluding brokerage, SFC transaction levy, AFRC transaction levy and the Stock Exchange trading fee thereon), or if the conditions of the Hong Kong Public Offering are not fulfilled in accordance with the section headed “*Structure of the Global Offering – Conditions of the Global Offering*” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, AFRC transaction levy, SFC transaction levy and the Stock Exchange trading fee, will be refunded, without interest. Any refund of your application monies will be made on or before Wednesday, December 14, 2022.

No temporary document of title will be issued in respect of the Shares. No receipt will be issued for sums paid on application. Share certificates and refund cheques are expected to be posted on or before Wednesday, December 14, 2022 as further described in the section “*How to Apply for Hong Kong Offer Shares – G. Despatch/Collection of Share Certificates and Refund Monies*” in the Prospectus. Share certificates will only become valid evidence of title at 8:00 a.m. (Hong Kong time) on Thursday, December 15, 2022, provided that the Global Offering has become unconditional and the right of termination described in the section headed “*Underwriting*” in the Prospectus has not been exercised. Dealings in the Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. (Hong Kong time) on Thursday, December 15, 2022. The Shares will be traded in board lots of 500 Shares.

The stock code of the Shares will be 1244.

This announcement is available for viewing on our website at www.3d-medicines.com and the website of the Stock Exchange at www.hkexnews.hk.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board and Executive Director

Hong Kong, November 29, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.